Introduction
As curve pertaining to morbidity and mortality of diabetes mellitus (DM) had positive slope in recent decades (1) and it is predicted to have 439 million diabetic patients in 2030 (2), more and more attention is paid to this issue. Additionally, myocardial dysfunctions such as diabetic cardiomyopathy (DCM) is more probable in DM patients compared to non-DMs (1). DCM is a pathological condition in which cardiomyocytes lose their potency to shift between different fuel substrate. Healthy heart uses long chain fatty acids (LCFA) providing 60-70% of ATP requirement to power contraction (3) (4) (5) (6) , but cardiac substrate utilization is altered in the diabetic condition leading excessive use of FA oxidation up to 90-100% of the heart's ATP needs (5) . As a result of metabolic derangements, myocardial dysfunction may appear. Complicated network regulating energy utilization and storage in myocardium is correlated with peraxisome prolifratoractivated receptors (PPARs) (7, 8) . They are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily, including three isoforms termed as PPARα, PPARδ/β (hereafter δ) and PPARγ (9). PPARs are activated by their selected ligands and form heterodimerize with retinoid X receptors (RXRs), respectively (10). Then the heterodimer binds to peroxisome proliferator response elements (PPREs), specific sequences in their target genes, and causes transcriptional switch (Fig. 1) . Control of FA consumption and storage is considered as a prior outcome of activated PPRE (11). Current review highlights and compares the role of PPARα and PPARδ in fatty acid oxidation (FAO) and DCM. 
Pathophysiology of cardiomyopathy

Heart fuel utilization and diabetes
The heart uses various substrates for energy metabolism, including glucose and FAs. Translocation of glucose transporters GLUT1 and GLUT4 to the cell membrane regulates glucose uptake (19). As GLUT1 is responsible for continuous basal glucose transport and GLUT4 is regulated by insulin and metabolic stress, GLUT4 function is affected in abnormal conditions. Another energy source is FA that is used as oxidative substrate in the adult heart. In healthy adult heart, FA oxidation provides 60-70% of the heart's ATP requirements (3) (4) (5) (25) (26) (27) (28) . As PKC is divided to three subgroups and each subgroup includes isotypes, they exert complicated effect in insulin pathway (29) . Among isotypes, PKCθ and PKCε clearly play a negative role in insulin pathway activation (30, 31) . PKCθ not only can phosphorylate IRS directly (32) , but also through intermediates. As indirect role, PKCθ activates stress Kinases IkBαKinaseβ (IKKβ) and c-Jun NH2-terminal Kinase (JNK) phosphorylating IRS and suppress insulin pathway (33) . PKCε can inhibit IRS via direct association with IRS (34) and also through direct phosphorylation (35) . Another lipid intermediate produced through FAO pathway is ceramide. It can induce insulin resistance at the level of Akt inhibition (36, 37) . Pharmacological inhibition of ceramide synthesis has presented an effective role in preventing lipid-induced insulin resistance in rats. As ceramides are synthesized through denovo pathway in cardiomyocytes (38) (Fig. 2) 
(42).
As different structure leads to different function and PPARs distribution is correlated with their function, each subtype fallows specific distribution pattern. PPARα is mainly distributed in tissues with high capacity for fatty acid oxidation pathway such as heart, brown adipose tissue, skin, slow-twitch skeletal muscle and liver (43-45). PPARδ is expressed predominantly in brain (46), adipose tissue, skin (45) and heart (47,48). Between these subtypes, PPARα is highly presented in liver and there are only some traces of PPARδ in hepatocytes (49). PPARα is coexpressed with CYP4A enzymes in this tissue. It binds to PPRE in the P4504A1 and 4A6 genes resulting in enzyme induction. Despite PPARα, PPARδ seems to have no regulating effects on the expression of CYP4A or any other P450 enzyme (50). Considering P450 enzymes and especially CYP4A are responsible for many drugs and other substrates metabolization, it is important to recognize their common ligands. Fibrates are considered as the oldest PPARα agonist. Natural carotenoid abundant in seafood can also stimulate PPARα (51). AVE8134 is another PPARα agonist newly found in 2012 and has amazing features (52). Unlike PPARα, PPARδ agonist is not well-known. GW50156 is an example of PPARδ agonist employed in last decade. As GW50156 was plausible to contribute to carcinogenesis and also athlete abuse, now it does not seem to be a good choice(53). Similarly to structure and tissue distribution PPRs functions can be analyzed. PPARα agonist (54) reduces serum triglycerides (TG) and increases high density lipoprotein (HDL), but they also shows carcinogenic outcomes in rodents. Similarly PPARδ activation causes reduction and elevation of TG and HDL in serum, respectively. This activation also triggers thermogenesis, weight loss and other metabolic possess (55, 56) . Glucose utilization and FAO, two main important sources of energy satisfying cellular metabolic demands, are strongly related to PPAR managements. Cardiomyocytes are very critical cells affected by PPARs function via metabolic controls (57) . 
PPAR alpha and metabolism in cardiac cell
Studies have demonstrated a serious role for PPARα by means of transcriptional control on genes involved in cardiac FA uptake and oxidation (58, 59) . In the heart, activation of PPARα increases the expression of genes participating to cellular FA utilization pathway in three major steps in the including fatty acid transport and esterification (60, 62) , FA mitochondrial import (63), mitochondrial (62) and peroxisomal β-oxidation ( Fig. 3) Studies on PPARα null mice also emerged an inability to pay for increased cardiac workloads and depression of cardiac contraction occurs. PPARα-knockout mice display decreased cardiac FAO rates, but lipid uptake was presumably not affected, and cardiomyocyte lipid accumulation occurred. On the other hand, transgenic mice that over express PPARα show an increase in the expression of genes encoding key enzymes involved in myocyte FA uptake and oxidation (65) . Moreover, PPARα activates pyruvate dehydrogenase kinase 4 (PKD4) (66 
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